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Abstract
Background: Expression levels of cell surface antigens such as CD38 and HLA-DR are related to HIV
disease stages. To date, the immunophenotyping of cell surface antigens relies on flow cytometry, allowing
estimation of 3–6 markers at a time. The recently described DotScan antibody microarray technology
enables the simultaneous analysis of a large number of cell surface antigens. This new technology provides
new opportunities to identify novel differential markers expressed or co-expressed on CD4+ and CD8+
T cells, which could aid in defining the stage of evolution of HIV infection and the immune status of the
patient.
Results: Using this new technology, we compared cell surface antigen expression on purified CD4+ and
CD8+ T cells between 3 HIV disease groups (long-term non-progressors controlling viremia naturally;
HIV+ patients on highly active antiretroviral therapy (HAART) with HIV plasma viral loads <50 copies/ml;
and HIV+ patients with viremia during HAART) and uninfected controls. Pairwise comparisons identified
17 statistically differential cell surface antigens including 5 novel ones (CD212b1, CD218a, CD183, CD3
epsilon and CD9), not previously reported. Notably, changes in activation marker expression were more
pronounced in CD8+ T cells, whereas changes in the expression of cell membrane receptors for cytokines
and chemokines were more pronounced in CD4+ T cells.
Conclusion: Our study not only confirmed cell surface antigens previously reported to be related to HIV
disease stages, but also identified 5 novel ones. Of these five, three markers point to major changes in
responsiveness to certain cytokines, which are involved in Th1 responses. For the first time our study
shows how density of cell surface antigens could be efficiently exploited in an array manner in relation to
HIV disease stages. This new platform of identifying disease markers can be further extended to study
other diseases.
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Background
HIV infection leads to characteristic alterations in the sub-
set composition of circulating CD4+ and CD8+ T lym-
phocytes. The activation marker CD38, in particular, and
its level of expression on CD8+ T cells is a marker that is
strongly associated with immune activation, particularly
during primary HIV-1 infection and progression to AIDS,
respectively [1-3]. Furthermore, decreased expression of
CD38 on CD8+ T cells is highly correlated with the effec-
tiveness of antiretroviral therapy [4-8] and lack of activa-
tion and expression of CD38 and HLA-DR on CD4+ T
cells correlates with long-term non-progression [9]. The
enumeration of CD4+ T-lymphocytes by flow cytometry is
used routinely in the clinical management of HIV-infected
individuals to monitor the severity of immunodeficiency
caused by HIV, and this acts as a basis for commencing
HAART and prophylaxis for Pneumocystis carinii pneumo-
nia [10]. However, more information on the progression
to immunodeficiency may be found in the detailed subset
composition of CD4+ and CD8+ T cells, but this is cur-
rently restricted to research studies.
To date, the immunophenotyping of CD antigens relies
on flow cytometry. Although very reliable, the flow
cytometry only allows estimation of 3–6 markers in a
given assay. The recently developed antibody microarray
technology enables the simultaneous analysis of a large
number of cell surface antigens on a single chip. This new
technology may permit the identification of novel differ-
ential markers expressed or co-expressed on CD4+ and
CD8+ T cells, which could aid in defining the stage of evo-
lution of HIV infection and the immune status of the
patient [11]. This antibody microarray also has significant
advantages over gene expression microarray because it
profiles cells at the level of protein expression, rather than
relying on quantifying mRNA expression levels. The
power of this technology as an adjunct to flow cytometry
was recently highlighted by Woolfson et al. [12], who used
a similar antibody microarray to demonstrate the conser-
vation of unique cell surface antigen mosaics in cryopre-
served PBMCs from HIV+ individuals.
Here, we have used an antibody microarray constructed
on the surface of a nitrocellulose coated slide to simulta-
neously analyze 135 different cell surface antigens (128
cluster of differentiation antigens plus 7 other surface
antigens) on peripheral blood CD4+ and CD8+ T cell sub-
sets from HIV+ and HIV- individuals. A comparison of
Table 1: Patient clinical details of viral load, CD4+ and CD8+ T cell counts at the time of sample collectiona
Patient Date Age CD4 counts (cells/µl) CD8 counts (cells/µl) Viral Load (copies/ml) Disease Group
1 20/06/06 55 380 790 <50 BDL
2 21/06/06 23 355 492 <50
3 27/06/06 61 691 1538 <50
4 27/06/06 42 425 721 <50
5 02/08/06 62 1037 607 <50
6 02/08/06 52 750 368 <50
7 23/08/06 52 799 449 <50
8 03/09/06 49 371 1818 <50
9 12/09/06 62 458 206 <50
10 13/09/06 39 901 870 <50
11 20/09/06 61 782 1936 <50
12 02/08/06 54 292 2989 352 VIR
13 21/06/06 38 560 980 49500
14 16/08/06 39 500 2064 32600
15 15/08/06 57 461 2306 46900
16 29/08/06 41 390 463 567
17 07/09/06 61 170 529 345
18 12/09/06 43 251 642 1700
19 15/09/06 50 265 170 105
20 20/09/06 38 231 1289 46900
21 03/10/06 45 286 1144 388
22 28/06/06 58 690 650 <50 LTNP
23 28/06/06 50 817 513 <50
24 18/07/06 78 880 860 <50
25 21/07/06 58 760 1800 <50
26 03/10/06 32 1121 790 128
a Plasma viral load was measured using the Quantiplex HIV RNA3.0 (Chiron bDNA) assay with a lower limit of detection of 50 HIV-1 copies/ml 
(Chiron Diagnostics, Halstead, United Kingdom).Retrovirology 2007, 4:83 http://www.retrovirology.com/content/4/1/83
Page 3 of 13
(page number not for citation purposes)
CD4+ and CD8+ T cells purified from peripheral blood of
three different HIV-infected patient groups (Table 1, HIV+
therapy naïve long-term non-progressors with high CD4+
and CD8+ T cell counts; HIV+ patients on HAART with
plasma viremia below detectable levels; and viremic
patients on HAART) and HIV seronegative individuals
showed 17 statistically differential cell surface antigens, 5
of which were novel. Furthermore, we demonstrate that
changes in the expression of activation markers were more
pronounced in CD8+ T cells, whereas changes in the
expression of cell membrane receptors for cytokines and
chemokines were more pronounced in CD4+ T cells.
Results
The pairwise comparisons of groups identified 17 statisti-
cally differential cell surface antigens, of which,
CD212b1, CD218a, CD183, CD3epsilon and CD9 have
not been previously reported in the context of HIV dis-
ease.
Discriminatory antibodies for CD4+ T cells
The signature pattern for each group and dot pattern from
which the raw data were derived is shown in Figure 1 and
2, respectively. In pairwise comparisons, CD4+ cells from
the HIV+ individuals differed from those of the NEG
group, as shown by the significant upregulation of CD71,
CD212b1, HLA-DR, CD95, CD57 and CD11b on the
CD4+ cells of one or more of the HIV+ groups, as shown
in Table 2. Although several other antigens showed
increased (CD218a and CD86 in VIR) or decreased
(CD27 in LTNP, CD45RA in BDL and CD28 in VIR)
expression compared to the NEG group, these did not
always reach statistical significance, with p values ranging
from 0.0540 to 0.0744.
Average CD11b and CD95 expression also increased in all
3 HIV+ groups compared to NEG individuals, but this
upregulation reached significance only in VIR, the p value
in BDL and LTNP ranging from 0.0589 to 0.0752. Varia-
bility in antigen expression within the latter groups may
contribute to this lack of significance, though the differ-
ences may reach significance with increased group sizes.
CD71, CD218a and CD54 were upregulated in both the
LTNP and the VIR groups compared with BDL, with p val-
ues of < 0.05 for all except CD54 in the LTNP-BDL com-
parison (p = 0.0695). LTNP-CD4 differed from BDL and/
or VIR groups in that CD71, HLA-DR, CD38, CD3epsilon
and CD183 were significantly upregulated.
Discriminatory antibodies for CD8+ T cells
The signature pattern for each group and representative
dot pattern from which the raw data were derived are
shown in Figure 3 and 4, respectively. In pairwise compar-
isons, CD8+ cells from HIV+ individuals differed from the
NEG group, as shown by the significant upregulation of
HLA-DR, CD57, CD11c, CD45RO and CD95 in one or
more of the HIV+ groups, with all 3 HIV+ groups showing
an increase in average HLA-DR, CD57, CD45RO and
CD95 expression (Table 3). There was significant down-
regulation of CD9 (in VIR) and CD27 (in LTNP), while
increases in CD212b1 (in LTNP and VIR) did not reach
significance (p = 0.0745–0.0776). CD38 was significantly
upregulated in the VIR group compared with BDL and
NEG groups. LTNP differed from BDL and VIR groups in
that CD8+ cells showed higher expression of CD11c,
CD16 and CD56, all differences being statistically signifi-
cant except CD56 in the LTNP-BDL comparison (p =
0.0871).
Discussion
To date the analysis of cell surface antigens on peripheral
blood lymphocytes of HIV infected individuals has been
largely carried out with whole PBMC using flow cytome-
try. In this study we used DotScan antibody microarray
technology (Medsaic Pty. Ltd, Sydney, Australia) to simul-
taneously analyze CD4+ and CD8+ T cell subsets
obtained from HIV+ individuals at different stages of HIV
disease for the expression of 135 different cell surface anti-
gens. For the first time, our study shows how the immu-
nophenotype of diverse blood cell types (in this case
CD4+ and CD8+ T cells) can be exploited to study various
HIV disease stages using antibody microarray technology.
Our analyses identified 17 statistically significant (p <
0.05) differentiating CD antigens distributed between
CD4+ and CD8+ T cells. Of these, 11 (CD71, CD212b1,
HLA-DR, CD57, CD95, CD11b, CD38, CD3epsilon,
CD218a, CD54 and CD183) were differential for CD4+ T
cells, while 10 (CD9, CD11c, CD16, CD38, CD27,
CD45RO, CD56, CD57, CD95 and HLA-DR) for CD8+ T
cells. Among these, CD212b1, CD218a, CD183,
CD3epsilon and CD9 have not been previously described
in relation to HIV disease.
For the activation markers, the results are in accordance
with previous studies using flow cytometry, confirming
the utility of this new technology. As previously reported
[13,14], HLA-DR and CD38 were significantly upregu-
lated on both CD4+ and CD8+ T cells during HIV infec-
tion. On CD4+ T cells, we observed significant
upregulation of HLA-DR in LTNP comparison to BDL and
NEG groups, suggesting that the level of activation of
CD4+ T cells from the BDL group was reduced by HAART
to a level similar to the NEG group. For CD38, a signifi-
cant increase was detected in the LTNP compared to the
BDL group. This may be due to the intermediate expres-
sion of CD38 on naïve CD4+ T cells, but this was not con-
firmed as this study did not differentiate between naïve
and memory CD4+ T cells. On CD8+ T cells, significant
upregulation of HLA-DR was observed in all HIV+ groups,Retrovirology 2007, 4:83 http://www.retrovirology.com/content/4/1/83
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Antibody response charts of CD4+ T cells Figure 1
Antibody response charts of CD4+ T cells. The bar charts represent the average immunophenotypes, or signatures, for each 
of the disease categories. Asterisks show the antigens which were significantly up-or down-regulated in paired comparisons of 
the disease groups. Labeling on the x-axis refers to monoclonal antibodies and their specificities against the corresponding anti-
gens and the y-axis the binding densities.Retrovirology 2007, 4:83 http://www.retrovirology.com/content/4/1/83
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while CD38 upregulation was seen in two HIV+ groups
(LTNP and VIR compared to the NEG group) and the pair-
wise comparison of VIR versus BDL group, which is in full
accordance with previous studies showing CD38 expres-
sion on CD8+ T cells is a marker associated with HIV dis-
ease progression [1,2]. The increased expression of
CD45RO on CD8+ T cells during HIV infection has also
been well documented [15], supporting our observation
that increases in CD45RO expression were significant, or
close to significant, on CD8+ T cells in all 3 HIV+ groups.
However, CD45RO modulation was not observed on
CD4+ T cells, confirming flow cytometry data [13], which
also showed that the proportion of CD4+ T cells express-
ing CD45RO remained relatively unchanged. Taken
together, it appears that for the activation markers men-
tioned above, significant changes in expression were more
pronounced on CD8+ than CD4+ T cells.
In addition, CD27 was significantly downregulated on
CD8+ T cells in the LTNP group compared to the NEG
group. It has been suggested in one study that HIV-specific
CD8+ T cells that have differentiated to the CD27- stage
are related to the delayed disease progression [16], while
another study has also observed a similar trend [17]. The
CD8+ T cells used in our study were not selected for HIV-
specificity, and hence the LTNP status appears to be
related to a general downregulation of CD27.
We also observed significantly increased CD95 expression
on both CD4+ and CD8+ T cells in the VIR group.
Although partially elevated CD95 levels were also
observed in BDL on HAART and LTNP groups, the
increases were not significant, which is consistent with
reduced immune activation in patients with reduced viral
replication. Increased Fas-receptor (CD95) expression on
CD4+ and CD8+ lymphocytes has previously been dem-
onstrated in a large group of HIV-1-infected patients when
Composite dot scan patterns of antibody binding for CD4+ T cells Figure 2
Composite dot scan patterns of antibody binding for CD4+ T cells. Half of a duplicate array was shown with the alignment dots 
"A" at left, top and bottom. Alignment dots are a mixture of CD44 and CD29 antibodies. (A) The key for CD antigens on the 
DotScan array, (B) NEG, (C) BDL, (D) VIR and (E) LTNP. Binding patterns shown here are representatives from each group. 
They may not fully reflect all the significant antigens from statistical analysis because of individual variability in antigen expres-
sion.Retrovirology 2007, 4:83 http://www.retrovirology.com/content/4/1/83
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compared against normal controls [18], and evidence also
suggests that poor responders to antiretroviral therapy
may have significantly higher CD95 expression [19].
These findings, together with our results, suggest that sig-
nificantly increased CD95 expression may relate to
antiretroviral therapy failure.
The most notable feature for the activation markers was
significant downregulation of CD9 expression on CD8+ T
cells in the VIR group compared to the NEG group. CD9
belongs to a transmembrane protein family known as the
tetraspanin family. It has been proposed that these pro-
teins act as scaffolding proteins by laterally organizing cel-
lular membranes via specific associations with each other
and distinct integrins. A recent study has shown that the
tetraspanin-enriched microdomains on the cell mem-
brane can function as gateways for HIV egress [20]. The
overall functional relevance of this antigen in the context
of HIV disease requires further investigation.
It has been suggested that CD57 is a marker for replicative
senescence [21,22]. We found a significant increase of
CD57 expression on CD8+ T cells in 2 of the 3 HIV
infected groups (BDL and VIR) compared with NEG
group, while on CD4+ T cells, only the VIR group showed
Table 3: Discriminatory antibodies for CD8+ T cellsa
Discriminatory Antibody Up(+)/Down(-) P Value
BDL vs. NEG
CD57 + 0.0272
CD45RO + 0.0307
HLA-DR + 0.0315
CD95 + 0.0538
LTNP vs. NEG
HLA-DR + 0.0039
CD11c + 0.0072
CD38 + 0.0219
CD27 PH - 0.0310
CD95 + 0.0545
CD57 + 0.0591
CD16 + 0.0631
CD212b1 + 0.0745
CD45RO + 0.0953
VIR vs. NEG
CD57 + 0.0006
CD45RO + 0.0067
CD38 + 0.0091
CD95 + 0.0091
HLA-DR + 0.0190
CD9 - 0.0268
CD212b1 + 0.0776
BDL vs. LTNP
CD11c - 0.0049
CD16 - 0.0093
CD56 - 0.0871
VIR vs. LTNP
CD11c - 0.0017
CD56 - 0.0121
CD16 - 0.0308
CD27PH + 0.0585
CD9 - 0.0862
VIR vs. BDL
CD38 + 0.0124
aSix paired comparisons of CD markers on CD8+ cells providing 
significant discrimination between patient groups, with relative 
changes in CD antigen binding in the former vs. the latter denoted by 
"+" and "-" to indicate increase and decrease, respectively. Antigens 
that did not achieve statistical significance (p > 0.05) but have been 
previously reported in HIV disease context or have been found to be 
significant in other pair comparisons are also shown in italic.
Table 2: Discriminatory antibodies for CD4+ T cellsa
Discriminatory Antibody Up(+)/Down(-) P Value
BDL vs. NEG
CD11b + 0.0599
CD95 + 0.0619
CD45RA - 0.0679
LTNP vs. NEG
CD71 + 0.0151
CD 212 b1 + 0.0307
HLA-DR + 0.0312
CD27 PH - 0.0560
CD11b + 0.0589
CD95 + 0.0752
VIR vs. NEG
CD71 + 0.0032
CD11b + 0.0227
CD57 + 0.0307
CD95 + 0.0349
CD28 - 0.0540
CD218a + 0.0732
CD86 + 0.0744
BDL vs. LTNP
CD183 - 0.0105
HLA-DR - 0.0270
CD38 - 0.0316
CD71 - 0.0385
CD218a - 0.0470
CD212 b1 - 0.0687
CD54 - 0.0695
VIR vs. LTNP
CD183 - 0.0451
CD3epsilon - 0.0489
CD27 PH + 0.0829
VIR vs. BDL
CD71 + 0.0195
CD218a + 0.0355
CD54 + 0.0421
aSix paired comparisons of CD markers on CD4+ cells providing 
significant discrimination between patient groups, with relative 
changes in CD antigen binding in the former vs. the latter denoted by 
"+" and "-" to indicate increase and decrease, respectively. Antigens 
that did not achieve statistical significance (p > 0.05) but have been 
previously reported in HIV disease context or have been found to be 
significant in other pair comparisons are also shown in italic. The "PH" 
in CD27 PH distinguishes this Pharmingen antibody (clone M-T271) 
from the Immunotech antibody 27 IM (clone 1A4-CD27).Retrovirology 2007, 4:83 http://www.retrovirology.com/content/4/1/83
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Antibody response charts of CD8+ T cells Figure 3
Antibody response charts of CD8+ T cells. The bar charts represent the average immunophenotypes, or signatures, for each 
of the disease categories. Asterisks show the antigens which were significantly up-or down-regulated in paired comparisons of 
the disease groups. Labeling on the x-axis refers to monoclonal antibodies and their specificities against the corresponding anti-
gens and the y-axis the binding densities.Retrovirology 2007, 4:83 http://www.retrovirology.com/content/4/1/83
Page 8 of 13
(page number not for citation purposes)
significantly increased expression. For HIV-specific CD8+
cells, diminished proliferative capacity results in a mem-
ory T cell population with reduced capacity to control
infections [23]. Although we did not study pure HIV-spe-
cific T cells, the significantly increased expression of CD57
seems to be directly related to disease progression. In con-
trast to CD57 which is linked to replicative senescence,
the transferrin receptor CD71 has been reported as a
marker for T cell proliferation [24]. DotScan analysis
showed that CD4+ T cells of LTNP and VIR groups
expressed significantly higher levels of expression of
CD71 than that of the BDL group. Consistent with studies
showing a significant increase in T cell turnover in HIV
infection [25-27], the upregulation of CD71 expression in
the LTNP group may indicate that the cells have recently
cycled. On the other hand, the upregulation of both CD57
and CD71 in the VIR group may indicate the activation
rather than the cell proliferation index [28]. Since CD71
constitutively cycles from endosomes to the cell surface
and back again [29], the microarray was significantly bet-
ter at detecting CD71 expression than flow cytometry.
Three cytokine receptors (CD183, CD218a, and
CD212b1) were found to be significantly upregulated on
CD4+ T cells in LTNP group, indicating a polarized Th1
cell immune response in LTNP group in HIV infection.
The CD4+ T cells of the LTNP group expressed higher lev-
els of CD183 (CXCR3) than those of the BDL and VIR
groups. Since CD183 is reported to be preferentially
expressed on Th1 versus Th2 cells in peripheral blood
[30,31] and to be found on a high percentage of CD4+ T
cells in type 1-dominated inflammatory processes [32],
the upregulation of this protein in the LTNP group may
imply a polarization towards a Th1 immune response in
LTNP group. CD218a (α chain of IL18R) was significantly
upregulated on the CD4+ T cells of LTNP and VIR groups
compared with the BDL group. CD212b1 (beta1 chain of
IL12R) was also significantly upregulated on the CD4+ T
cells of the LTNP group compared to the NEG group. A
Composite dot scan patterns of antibody binding for CD8+ T cells Figure 4
Composite dot scan patterns of antibody binding for CD8+ T cells. Half of a duplicate array was shown with the alignment dots 
"A" at left, top and bottom. Alignment dots are a mixture of CD44 and CD29 antibodies. (A) The key for CD antigens on the 
DotScan array, (B) NEG, (C) BDL, (D) VIR and (E) LTNP. Binding patterns shown here are representatives from each group. 
They may not fully reflect all the significant antigens from statistical analysis because of individual variability in antigen expres-
sion.Retrovirology 2007, 4:83 http://www.retrovirology.com/content/4/1/83
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previous study on the expression of cytokine receptors on
lymphocytes from patients suffering from a disorder asso-
ciated with raised Th1 cytokine production showed that
the percentage of CD218a+ and CD212b1+ cells within
the CD4+CD45RA+ subset is significantly higher in these
patients than in healthy subjects [33]. By analogy, in HIV
disease, the upregulation of CD218a and CD212b1 in
HIV disease may also indicate a chronically polarized
immune response towards Th1 in LTNP group. With
regard to cytokine receptors, although previous studies
have shown that the level of CD127 (IL-7R) expression
represents a major difference between HIV+ subjects and
controls [34-36], we did not observe any difference
between groups. This is due to the lack of cell binding to
CD127 antibody on the microarray, which may attribute
to either low cell numbers of CD127+ or the low affinity
of this antibody used.
With regard to cell signaling, CD3epsilon expression on
CD4+ T cells was found to be significantly lower in the
VIR group than in LTNP, which indicates that the expres-
sion level of CD3epsilon can be used to differentiate VIR
and LTNP groups. A previous study on HIV+ patients has
shown that the expression of CD3 complex (gamma,
delta, epsilon) is downregulated on T cells compared to
healthy control [37], while our study is the first to relate
one of the components of CD3 complex, CD3epsilon, to
HIV disease status, yet the biological significance of
CD3epsilon expression in HIV disease requires further
elucidation. Interestingly, the significant changes in
expression of cell membrane receptors mentioned above
(CD183, CD218a, CD212b1 and CD3epsilon) were all
observed on CD4+ T cells, but not on CD8+ T cells.
Significant group-specific differences were also found for
3 cell adhesion molecules (CD11b, CD11c and CD54),
which may have significant implications for the patho-
genesis of HIV disease, since adhesion molecules can
affect cell distribution, migration and immune response.
CD11b was significantly upregulated on CD4+ T cells in
the VIR group compared with the NEG group. This
increase was also seen in the BDL and LTNP groups, but
was not statistically significant. Although there is evidence
for increases in CD8+/CD11b+ T cells during progression
of HIV infection in asymptomatic patients [38], we are not
aware of any previous reports of modulations in CD11b
expression on CD4+ T cells of HIV+ patients. CD11c,
which has mainly been studied in relation to dendritic
cells in HIV disease, was found to be expressed at signifi-
cantly higher levels on CD8+ T cells in the LTNP group
than in the other 2 HIV+ groups. Although the upregula-
tion of CD11c after HIV-1 infection has been reported at
mRNA levels [39], it has not previously been documented
at protein levels. CD54, also known as intercellular adhe-
sion molecule-1, was significantly elevated on CD4+ T
cells in VIR compared to the BDL group. This is consistent
with a previous report of the involvement of intercellular
adhesion molecule-1 in syncytia formation and virus
infectivity and the increase in its expression on lym-
phocytes in HIV infection [40].
Interestingly, the expression levels of two NK associated
receptors on CD8+ T cells, CD16 and CD56 were signifi-
cantly higher for LTNP than for BDL and VIR groups,
though not all detected differences reached statistical sig-
nificance (p = 0.0093 to 0.0871). CD56 is expressed on a
subset of CD8+ T cells (mature cytolytic effector cells) and
it has previously been suggested that the defective expres-
sion of CD56 on these cells in HIV-infected individuals
could contribute to the decreased peripheral blood T-cell
cytotoxicity found in HIV infection [41]. These findings,
together with ours, support the hypothesis that the CD8+
T cells from LNTP may have stronger cytotoxic activity
than those from other HIV+ individuals. CD16 expression
on CD8+ T cells in HIV disease has not previously been
reported. However, increases in CD8 T cells expressing NK
associated receptors have been reported in melanoma
patients, and these cells display an effector phenotype
[42]. Similar changes may also occur in HIV patients, and
the implication of these changes needs further investiga-
tion.
Conclusion
DotScan antibody microarray technology enabled the
identification of 3 distinct HIV disease groups based on an
extensive immunophenotypic characterization of the
patients' CD4+ and CD8+ peripheral blood T cells. This
research not only confirmed previously reported findings
from flow cytometric investigations, but also demon-
strated the power of the antibody microarray technology,
by identifying 5 new cell surface antigens that may poten-
tially be associated with HIV disease stages. Simultaneous
screening for a large number of cell surface antigens
revealed that changes in the expression of activation
markers were more pronounced in CD8+ T cells, whereas
changes in the expression of cell membrane receptors for
cytokines and chemokines were more pronounced in
CD4+ T cells.
Since these changes were shown to be related to the dis-
ease status, we suggest that the use of this technology will
facilitate further investigation of the causes and control of
HIV disease progression and eventually lead to a better
understanding of the pathogenesis of the disease. Our
study is the first to demonstrate how density of cell surface
antigens can be efficiently exploited in an array manner in
relation to disease stages. This new platform of identifying
disease markers can be further extended to study other
diseases. Increasing patient group size should correspond-
ingly improve the statistical significance of the observedRetrovirology 2007, 4:83 http://www.retrovirology.com/content/4/1/83
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differences in antigen expression associated with disease
stage. A simplified protocol of direct purification of CD4+
or CD8+ T cells from whole blood may also allow a
broader diagnostic utility. Serial time course studies of
patients during their disease progression should also pro-
vide useful information on the modulation of cell surface
antigens over time and could potentially identify new
prognostic and therapeutic markers relevant to HIV dis-
ease, enabling prediction of patient responsiveness to
therapy.
Methods
Patient profiles
Blood (20 ml EDTA) was obtained from 26 HIV+ individ-
uals attending HIV clinic at the Westmead Hospital (Table
1) and 5 HIV- healthy individuals from the Australian Red
Cross, Sydney. This study has been approved by the West-
ern Sydney Area Health Services and all blood samples
were obtained upon written informed consent. The
patient groups were: (1) Healthy HIV- individuals (NEG;
n = 5); (2) HIV+ individuals on HAART with "below
detectable levels" of plasma viremia and classed as
patients controlling viremia with HAART (BDL; n = 11 for
CD4; n = 10 for CD8; one CD8 sample was excluded as it
failed to meet the internal control criteria); (3) HIV+ indi-
viduals on HAART with detectable plasma viremia (VIR; n
= 9 for CD4; n = 10 for CD8; one CD4 sample was
excluded as it failed to meet the internal control criteria);
(4) Treatment naïve HIV+ long-term non-progressors
(LTNP; n = 5), who have maintained high CD4+ T cell
counts (>500 cells/µl), with the average infection time of
>20 years and natural control of plasma viremia to below
detectable levels. One of the 5 LTNP patients (patient 26)
in this category did show very low plasma viremia (128
HIV RNA copies/ml of plasma), but was included because
this patient met all the other selection criteria.
Purification of CD4+ and CD8+ T cells
A single blood sample (20 ml) was obtained from each
patient. After separation of plasma, PBMC were isolated
by Ficoll-gradient centrifugation and then purified. CD4+
and CD8+ T cells, respectively, were obtained by positive
isolation with antibody-conjugated magnetic beads
according to the manufacturer's instructions (Dynal Bio-
tech, Oslo, Norway). Flow-cytometric analysis performed
on separated CD4+ and CD8+ T cell populations demon-
strated that in CD4+ T cell isolations 99.2% ± 0.165%
(mean ± SD) of cells were single positive for CD4 marker,
while 99.1% ± 0.128 (mean ± SD) of purified CD8+ cells
were single positive for CD8 marker [43]. Absence of
binding of purified CD8+ T cells to the CD4 antibody and
vice versa further confirmed that cross contamination was
negligible and would not compromise assay specificity.
CD antibody microarrays
Medsaic Pty. Ltd. (Eveleigh, NSW, Australia) provided the
DotScanTM microarrays, prepared as previously described
[44]. Monoclonal antibodies were purchased from the fol-
lowing companies: Coulter and Immunotech from Beck-
man Coulter (Gladesville, NSW, Australia), Pharmingen
(BD Biosciences, North Ryde, NSW, Australia), Biosource
International (Applied Medical, Stafford City, QLD, Aus-
tralia), Serotec (Australian Laboratory Services, Sydney,
NSW, Australia), Sigma-Aldrich (Castle Hill, NSW, Aus-
tralia), Biotrend, Biodesign and MBL (Jomar Diagnostics,
Stepney, SA, Australia), Chemicon Australia (Boronia,
VIC, Australia), Leinco Technologies (St. Louis, MO, USA)
and Calbiochem (Merck, Kilsyth, VIC, Australia). Anti-
body solutions were reconstituted as recommended, and
stored in aliquots with 0.1% (w/v) BSA at -80°C;
Pharmingen antibodies were generally stored at 4°C.
Antibodies were used for making microarrays at concen-
trations ranging from 50–1000 µg protein/ml.
Immunophenotyping of ex vivo purified CD4+ and CD8+ T 
cells
Purified CD4+ and CD8+ T cell populations were tested
on antibody microarrays using DotScan technology as
previously described [45]. Briefly, a 300 µL aliquot of
either purified CD4+ or CD8+ cell suspension (= 4 × 106
cells) was incubated for 30 min on the microarray chip,
after which unbound cells were removed by gentle immer-
sion in PBS. Captured cells were fixed and imaged using a
Medsaic DotReader™ and dot intensities were quantified
for each antigen in duplicate using Dotscan data analysis
software on an 8-bit pixel grey scale from 0–255 that
reflects the level of expression of a particular antigen as
well as the proportion of cells expressing that antigen
[45]. The limit of detection using the optical scanner is
approximately 100 cells/antibody dot. Each microarray
has alignment dots, which establishes the location of each
dot on the array and also served as the internal control to
measure the distribution of cells. The dot pattern obtained
is the immunophenotype of that population of leuko-
cytes.
The main strength of antibody microarray is its capacity to
rapidly screen for a large number of antigens, producing
an extensive immunophenotype using a relatively small
number of cells in a single assay. However, it would not
provide all of the information obtained by flow cytometry
such as multiparameter analysis on single cells and level
of antigen expression per cell. When the same sample is
tested by the same operator on 3 different arrays (unpub-
lished data), the coefficient of variation (CV) for binding
densities tends to be low (8.3%) for dots of high density
(>50 pixels), but higher (33.3%) for dots of low density
(2–50 pixels). Reproducible dot binding patterns can beRetrovirology 2007, 4:83 http://www.retrovirology.com/content/4/1/83
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achieved if a technically consistent standard assay proto-
col is followed for all assays.
Statistical derivations
The objective of this analysis was to identify antibody dots
showing differential levels of binding of cells derived
from different disease categories, where the sample cate-
gories had been established a priori. No fewer than 5 sam-
ples per group were included for statistical analysis, as
required for the application of Medsaic's standard bioin-
formatics tools used in this study. Data were log trans-
formed and log transformed antibody bindings have a
symmetrical distribution which shows reasonable stabil-
ity of variance with mean expression. Following transfor-
mation, the distributional properties for individual
antibodies were examined using box plots and kernel den-
sity estimators. Differential expression was analysed on an
antibody-by-antibody basis. Individual intra-group com-
parisons were first carried out, followed by pairwise inter-
group comparisons between the four study groups. The
"Antibody Ranking" analysis of the array binding results
was carried out as a one way analysis of variance, which
provided p values and adjusted p values for each antibody
and ranked the antibodies in order of significance. P val-
ues were adjusted using Holm's method, a conservative
approach to maintain strong control of an inflated type I
error rate [46]. Differential expression of antigens was
identified by paired comparisons of the 4 study groups,
with differences reaching statistical significance when the
adjusted p value was less than 0.05.
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